PMID- 25563556
OWN - NLM
STAT- MEDLINE
DCOM- 20160406
LR  - 20220114
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 8
DP  - 2015
TI  - Real-life comparison of severe vascular events and other non-hematological 
      complications in patients with chronic myeloid leukemia undergoing second-line 
      nilotinib or dasatinib treatment.
PG  - 2309-14
LID - 10.3109/10428194.2014.994205 [doi]
AB  - We retrospectively analyzed the rates of significant non-hematological adverse 
      events (AEs) in 105 patients with chronic myeloid leukemia (CML) treated with 
      second-generation tyrosine kinase inhibitor (TKIs) dasatinib or nilotinib used as 
      second-line therapy in Polish tertiary care centers. Our analysis revealed that 
      in a "real life setting," nearly half of patients with CML on second-generation 
      TKIs suffer from therapy complications. Grade 2-5 non-hematological AEs were 
      observed in 40% of patients treated with nilotinib and in 42% treated with 
      dasatinib (p=0.83). Severe vascular events including peripheral artery occlusive 
      disease (PAOD) occurred in 11% of patients on nilotinib and 4% on dasatinib 
      (p=0.16). Pleural effusion occurred more often in the dasatinib group (26%) than 
      in the nilotinib group (2%) (p=0.003). Importantly, most AEs occurred late, after 
      more than 1 year of treatment. Since AEs are most often the reason for poor 
      therapy compliance, careful monitoring of tolerability is crucial for an optimal 
      treatment response in CML.
FAU - Gora-Tybor, Joanna
AU  - Gora-Tybor J
AD  - a Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
FAU - Medras, Ewa
AU  - Medras E
AD  - b Department and Clinic of Hematology , Blood Neoplasms, and Bone Marrow 
      Transplantation , Wroclaw , Poland.
FAU - Calbecka, Malgorzata
AU  - Calbecka M
AD  - c Department of Hematology , Nicolaus Copernicus Hospital , Torun , Poland.
FAU - Kolkowska-Lesniak, Agnieszka
AU  - Kolkowska-Lesniak A
AD  - a Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
FAU - Ponikowska-Szyba, Edyta
AU  - Ponikowska-Szyba E
AD  - d Department of Hematology , Holycross Cancer Center , Kielce , Poland.
FAU - Robak, Tadeusz
AU  - Robak T
AD  - e Department of Hematology , Medical University of Lodz , Lodz , Poland.
FAU - Jamroziak, Krzysztof
AU  - Jamroziak K
AD  - a Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
LA  - eng
PT  - Journal Article
DEP - 20150305
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - F41401512X (nilotinib)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Dasatinib/*adverse effects/therapeutic use
MH  - Drug Substitution
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*complications/drug 
      therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*etiology
MH  - Pleural Effusion/etiology
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
MH  - Pyrimidines/*adverse effects/therapeutic use
MH  - Retreatment
MH  - Retrospective Studies
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - CML
OT  - PAOD
OT  - dasatinib
OT  - nilotinib
OT  - non-hematological complication
OT  - vascular complication
EDAT- 2015/01/08 06:00
MHDA- 2016/04/07 06:00
CRDT- 2015/01/08 06:00
PHST- 2015/01/08 06:00 [entrez]
PHST- 2015/01/08 06:00 [pubmed]
PHST- 2016/04/07 06:00 [medline]
AID - 10.3109/10428194.2014.994205 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015;56(8):2309-14. doi: 10.3109/10428194.2014.994205. Epub 2015 
      Mar 5.